Lonza has announced that its Niacinamide Plant in Nansha, China will be shut down in November and December 2019 for routine maintenance.
Lonza has announced that its Niacinamide Plant in Nansha, China will be shut down in November and December 2019 for routine maintenance. The Nansha site is the production plant for Niacinamide (vitamin B3), a product that is mainly exported to European countries, the Americas, Japan, and Australia, as well as the Chinese market. The routine maintenance and process optimization is expected to take six weeks at the end of the year, the company stated in an Oct. 22, 2019 press release.
In the press release, Lonza confirmed that during the showdown period it will fulfill all orders and contractual obligations.
Source: Lonza
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.